JP2003503312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003503312A5 JP2003503312A5 JP2000616237A JP2000616237A JP2003503312A5 JP 2003503312 A5 JP2003503312 A5 JP 2003503312A5 JP 2000616237 A JP2000616237 A JP 2000616237A JP 2000616237 A JP2000616237 A JP 2000616237A JP 2003503312 A5 JP2003503312 A5 JP 2003503312A5
- Authority
- JP
- Japan
- Prior art keywords
- phe
- val
- lys
- ala
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 238000011503 in vivo imaging Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- SICITCLFXRGKJW-IIZANFQQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 SICITCLFXRGKJW-IIZANFQQSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13259299P | 1999-05-05 | 1999-05-05 | |
| US60/132,592 | 1999-05-05 | ||
| PCT/CA2000/000515 WO2000068263A2 (en) | 1999-05-05 | 2000-05-04 | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003503312A JP2003503312A (ja) | 2003-01-28 |
| JP2003503312A5 true JP2003503312A5 (enExample) | 2007-08-02 |
Family
ID=22454745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000616237A Pending JP2003503312A (ja) | 1999-05-05 | 2000-05-04 | 立体選択的抗原線維形成ペプチドおよびそのペプチド模倣体 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1173480B1 (enExample) |
| JP (1) | JP2003503312A (enExample) |
| AT (1) | ATE384077T1 (enExample) |
| AU (1) | AU4529800A (enExample) |
| CA (1) | CA2388092A1 (enExample) |
| DE (1) | DE60037800D1 (enExample) |
| IL (1) | IL146009A0 (enExample) |
| WO (1) | WO2000068263A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11779629B2 (en) | 2016-11-09 | 2023-10-10 | The University Of British Columbia | Compositions comprising cyclic peptides derived from an A-beta peptide |
| US11905318B2 (en) | 2015-11-09 | 2024-02-20 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide |
| US11970522B2 (en) | 2015-11-09 | 2024-04-30 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0866805A1 (en) | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6852696B2 (en) | 1999-03-26 | 2005-02-08 | The University Of Texas System | Inhibitors of glycosaminoglycans |
| US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| AU784312B2 (en) * | 1999-11-29 | 2006-03-09 | Bellus Health (International) Limited | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| US6670399B2 (en) | 1999-12-23 | 2003-12-30 | Neurochem (International) Limited | Compounds and methods for modulating cerebral amyloid angiopathy |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| WO2002076173A2 (en) * | 2001-03-21 | 2002-10-03 | The University Of Texas System | Inhibitors of glycosaminoglycans |
| DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
| GB2380998B (en) * | 2001-08-03 | 2004-10-20 | Marc Kvansakul | D-amino acid peptide for security tagging |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| EP1380290A1 (en) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
| JP2006512417A (ja) * | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
| EP1838854B1 (en) | 2004-12-15 | 2012-10-31 | Janssen Alzheimer Immunotherapy | Antibodies that recognize Beta Amyloid Peptide |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| GB0608960D0 (en) * | 2006-05-05 | 2006-06-14 | St Georges Hosp Medical School | Imaging agent |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| WO2008050133A2 (en) * | 2006-10-27 | 2008-05-02 | Zapaloid Limited | Inhibition of beta-amyloid aggregation |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| JP5889529B2 (ja) | 2007-07-27 | 2016-03-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | アミロイド原性疾患の処置 |
| GB0716885D0 (en) | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| JP5804463B2 (ja) | 2012-12-27 | 2015-11-04 | 国立研究開発法人科学技術振興機構 | 環状ペプチド及びこれを含有する医薬 |
| GB201613999D0 (en) | 2016-08-16 | 2016-09-28 | Neuro-Bio Ltd | Neurodegenerative disorders |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| EP0866805A1 (en) * | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| DK0929574T3 (da) * | 1996-08-27 | 2005-10-31 | Praecis Pharm Inc | Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer |
| JPH10182695A (ja) * | 1996-12-27 | 1998-07-07 | Teikoku Seiyaku Co Ltd | ｇｐ１２０に対して親和性を有するペプチド |
-
2000
- 2000-05-04 DE DE60037800T patent/DE60037800D1/de not_active Expired - Lifetime
- 2000-05-04 IL IL14600900A patent/IL146009A0/xx unknown
- 2000-05-04 AT AT00926599T patent/ATE384077T1/de not_active IP Right Cessation
- 2000-05-04 EP EP00926599A patent/EP1173480B1/en not_active Expired - Lifetime
- 2000-05-04 AU AU45298/00A patent/AU4529800A/en not_active Abandoned
- 2000-05-04 JP JP2000616237A patent/JP2003503312A/ja active Pending
- 2000-05-04 WO PCT/CA2000/000515 patent/WO2000068263A2/en not_active Ceased
- 2000-05-04 CA CA002388092A patent/CA2388092A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11905318B2 (en) | 2015-11-09 | 2024-02-20 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide |
| US11970522B2 (en) | 2015-11-09 | 2024-04-30 | The University Of British Columbia | Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide |
| US11779629B2 (en) | 2016-11-09 | 2023-10-10 | The University Of British Columbia | Compositions comprising cyclic peptides derived from an A-beta peptide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003503312A5 (enExample) | ||
| JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| US8507447B2 (en) | Treatments for gastrointestinal disorders | |
| US8933030B2 (en) | Treatments for gastrointestinal disorders | |
| HK1206971A1 (en) | Methods for reducing cd36 expression | |
| JP2011518179A5 (enExample) | ||
| IL192046A (en) | Intact and peptide intestinal fragments and methods of use | |
| US20170065670A1 (en) | Methods for treating immune mediated neurological diseases | |
| CN103501801A (zh) | 甲状旁腺激素类似物、其组合物和用途 | |
| US9650417B2 (en) | Treatments for gastrointestinal disorders | |
| US10618938B2 (en) | Compositions for colon cleansing and the treatment of gastrointestinal disorders | |
| JP7333929B2 (ja) | ヒスタチンおよびその使用方法 | |
| WO2012170804A1 (en) | Treatments for gastrointestinal disorders | |
| US9527887B2 (en) | Treatments for gastrointestinal disorders | |
| JPH0625288A (ja) | ペプチドまたはその塩 | |
| JP2023522015A (ja) | サルコペニアを逆行させる方法、組成物及びその使用 | |
| JP2009502976A (ja) | 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート | |
| US7314867B2 (en) | Pharmaceutical composition comprising a retro-iverso isomer peptide | |
| JP2025538651A (ja) | 胃腸管及び／又は内分泌障害治療のためのｇａｌｒ２作用剤の用途 | |
| JPH09502427A (ja) | オキシトシン拮抗薬活性を示すペプチド | |
| WO2006097416A1 (en) | Compounds for use in the prevention and treatment of alzheimer's disease | |
| HK1212718B (zh) | 用於减少cd36表达的方法 | |
| JP2001270897A (ja) | 生理活性ペプチド |